vs
ASP Isotopes Inc.（ASPI）与CytomX Therapeutics, Inc.（CTMX）财务数据对比。点击上方公司名可切换其他公司
CytomX Therapeutics, Inc.的季度营收约是ASP Isotopes Inc.的1.1倍（$18.7M vs $16.7M），ASP Isotopes Inc.同比增速更快（1295.7% vs -25.7%），CytomX Therapeutics, Inc.自由现金流更多（$-15.8M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
ASPI vs CTMX — 直观对比
营收规模更大
CTMX
是对方的1.1倍
$16.7M
营收增速更快
ASPI
高出1321.4%
-25.7%
自由现金流更多
CTMX
多$31.7M
$-47.4M
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $18.7M |
| 净利润 | — | $-154.0K |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | -6.9% |
| 净利率 | — | -0.8% |
| 营收同比 | 1295.7% | -25.7% |
| 净利润同比 | -586.8% | 97.6% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPICTMX
| Q4 25 | $16.7M | — | ||
| Q3 25 | $4.9M | — | ||
| Q2 25 | — | $18.7M | ||
| Q1 25 | — | $50.9M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $33.4M | ||
| Q2 24 | — | $25.1M | ||
| Q1 24 | — | $41.5M |
净利润ASPICTMX
| Q4 25 | — | — | ||
| Q3 25 | $-12.9M | — | ||
| Q2 25 | — | $-154.0K | ||
| Q1 25 | — | $23.5M | ||
| Q4 24 | — | $18.9M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | — | $-6.5M | ||
| Q1 24 | — | $13.8M |
毛利率ASPICTMX
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率ASPICTMX
| Q4 25 | — | — | ||
| Q3 25 | -306.1% | — | ||
| Q2 25 | — | -6.9% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | — | 46.4% | ||
| Q3 24 | — | 12.3% | ||
| Q2 24 | — | -33.7% | ||
| Q1 24 | — | 28.1% |
净利率ASPICTMX
| Q4 25 | — | — | ||
| Q3 25 | -263.7% | — | ||
| Q2 25 | — | -0.8% | ||
| Q1 25 | — | 46.2% | ||
| Q4 24 | — | 49.6% | ||
| Q3 24 | — | 17.2% | ||
| Q2 24 | — | -26.0% | ||
| Q1 24 | — | 33.3% |
每股收益（稀释后）ASPICTMX
| Q4 25 | — | — | ||
| Q3 25 | $-0.15 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $49.0M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $119.9M |
| 总资产 | $498.0M | $175.1M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPICTMX
| Q4 25 | $333.3M | — | ||
| Q3 25 | $113.9M | — | ||
| Q2 25 | — | $49.0M | ||
| Q1 25 | — | $47.6M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $40.6M | ||
| Q2 24 | — | $43.2M | ||
| Q1 24 | — | $36.2M |
总债务ASPICTMX
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASPICTMX
| Q4 25 | $204.2M | — | ||
| Q3 25 | $74.1M | — | ||
| Q2 25 | — | $119.9M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $-456.0K | ||
| Q3 24 | — | $-23.5M | ||
| Q2 24 | — | $-31.2M | ||
| Q1 24 | — | $-31.7M |
总资产ASPICTMX
| Q4 25 | $498.0M | — | ||
| Q3 25 | $225.9M | — | ||
| Q2 25 | — | $175.1M | ||
| Q1 25 | — | $98.5M | ||
| Q4 24 | — | $120.5M | ||
| Q3 24 | — | $139.0M | ||
| Q2 24 | — | $159.2M | ||
| Q1 24 | — | $184.7M |
负债/权益比ASPICTMX
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-15.8M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $-15.8M |
| 自由现金流率自由现金流/营收 | -284.7% | -84.6% |
| 资本支出强度资本支出/营收 | 57.9% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-77.7M |
8季度趋势，按日历期对齐
经营现金流ASPICTMX
| Q4 25 | $-37.8M | — | ||
| Q3 25 | $-8.9M | — | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.0M | ||
| Q4 24 | — | $-19.9M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-19.5M | ||
| Q1 24 | — | $-26.0M |
自由现金流ASPICTMX
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.2M | ||
| Q4 24 | — | $-20.0M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-19.6M | ||
| Q1 24 | — | $-26.2M |
自由现金流率ASPICTMX
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q2 25 | — | -84.6% | ||
| Q1 25 | — | -41.6% | ||
| Q4 24 | — | -52.5% | ||
| Q3 24 | — | -62.1% | ||
| Q2 24 | — | -78.2% | ||
| Q1 24 | — | -63.1% |
资本支出强度ASPICTMX
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.3% |
现金转化率ASPICTMX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
